Throwing a spotlight on under-recognized manifestations of Gaucher disease: Pulmonary involvement, lymphadenopathy and Gaucheroma

被引:20
作者
Ramaswami, Uma [1 ]
Mengel, Eugen [2 ]
Berrah, Abdelkrim [3 ]
AlSayed, Moeenaldeen [4 ,5 ]
Broomfield, Alex [6 ]
Donald, Aimee [7 ]
El Dein, Hadeel M. Seif [8 ]
Freisens, Selena [9 ]
Hwu, Wuh-Liang [10 ]
Peterschmitt, M. Judith [9 ]
Yoo, Han-Wook [11 ,12 ]
Abdelwahab, Magy [13 ,14 ]
机构
[1] Royal Free London NHS Fdn Trust, London, England
[2] SphinCS Hocheim, Hochheim, Germany
[3] Univ Hosp Bab El Oued, Algiers, Algeria
[4] Alfaisal Univ, Riyadh, Saudi Arabia
[5] King Faisal Specialist Hosp & Res Ctr, Riyadh, Saudi Arabia
[6] Manchester Fdn NHS Trust, Manchester Ctr Genom Med, Willink Biochem Genet Unit, Manchester, Lancs, England
[7] St Marys Hosp, Willink Unit, Manchester, Lancs, England
[8] Cairo Univ, Abou Rish Pediat Hosp, Cairo, Egypt
[9] Sanofi Genzyme Inc, Cambridge, MA USA
[10] Natl Taiwan Univ Hosp, Taipei, Taiwan
[11] Childrens Hosp, Asan Med Ctr, Seoul, South Korea
[12] Univ Ulsan, Coll Med, Seoul, South Korea
[13] Cairo Univ, Pediat Hosp, Cairo, Egypt
[14] Kasr Elainy Hosp, Social & Prevent Med Ctr, Cairo, Egypt
关键词
Gaucher disease; Pulmonary involvement; Pulmonary hypertension; Lymphadenopathy; Protein-losing enteropathy; Gaucheroma; ENZYME REPLACEMENT THERAPY; PROTEIN-LOSING ENTEROPATHY; MESENTERIC LYMPHADENOPATHY; HEPATIC GAUCHEROMA; LUNG INVOLVEMENT; TYPE-1; DETERMINANTS; HYPERTENSION; COMPLICATION; PHENOTYPE;
D O I
10.1016/j.ymgme.2021.06.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Gaucher disease (GD) is a rare lysosomal storage disorder classically subdivided into type 1 (nonneuronopathic) GD, and types 2 and 3 (neuronopathic) GD. It is typically characterized by clinical manifestations including anemia, thrombocytopenia, hepatosplenomegaly, bone lesions, and (in more severe forms) neurological impairment. However, less-commonly reported and often under-recognized manifestations exist, which potentially have a significant impact on patient outcomes. Greater efforts are needed to understand, recognize, and manage these manifestations. Objectives: This review provides a synthesis of published information about three under-recognized GD manifestations (pulmonary involvement, lymphadenopathy, and Gaucheroma) and recommends diagnostic, management, and treatment strategies based on the available literature and author experience. The authors aim to raise awareness about these serious, progressive, and sometimes life-threatening conditions, which are often diagnosed late in life. Conclusions: Little is known about the incidence, pathophysiology, prognostic factors, and optimal management of pulmonary involvement, lymphadenopathy, and Gaucheroma in patients with GD. Enzyme replacement therapy (ERT) has shown limited efficacy for the prevention and treatment of these manifestations. More research is needed to evaluate the potential effect of substrate reduction therapy (SRT) with glucosylceramide synthase (GCS) inhibitors, and to develop additional approaches to treat these GD manifestations. Improvements in data collection registries and international data-sharing are required to better understand the impact of these manifestations on GD patients, help develop effective management strategies, and, ultimately, improve patient outcomes. (c) 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:335 / 344
页数:10
相关论文
共 68 条
  • [1] Lung involvement of Egyptian children with type 1 and 3 Gaucher disease: does enzyme replacement therapy have a role in reversing symptoms and can it be considered an index of disease severity?
    Abdelwahab, Magy
    Seif, Hadeel
    Hesham, Rania
    [J]. MOLECULAR GENETICS AND METABOLISM, 2014, 111 (02) : S16 - S17
  • [2] Cardiac assessment in Egyptian type 3 Gaucher disease and report of calcifications in homozygous L444P mutation
    Abdelwahab, Magy
    Fattouh, Aya
    Hamza, Hala
    Abdelaziz, Doaa
    [J]. MOLECULAR GENETICS AND METABOLISM, 2017, 120 (1-2) : S17 - S17
  • [3] Mesenteric and Mediastinal Lymphadenopathy in Egyptian Children With Gaucher Disease Types 1 and 3 Treated With Enzyme Replacement Therapy
    Abdelwahab, Magy
    SeifEldien, Hadeel M.
    [J]. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2015, 37 (05) : e316 - e322
  • [4] The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease
    Altarescu, G
    Hill, S
    Wiggs, E
    Jeffries, N
    Kreps, C
    Parker , CC
    Brady, RO
    Barton, NW
    Schiffmann, R
    Bannarjee, TK
    Crutchfield, K
    Frei, K
    McKee, MA
    Moore, DF
    Tournay, A
    [J]. JOURNAL OF PEDIATRICS, 2001, 138 (04) : 539 - 547
  • [5] Pulmonary involvement of Gaucher's disease in children: a common presentation in Saudi Arabia
    Banjar, H
    [J]. ANNALS OF TROPICAL PAEDIATRICS, 1998, 18 (01): : 55 - 59
  • [6] Bennett Lunawati L, 2018, P T, V43, P274
  • [7] Berrah A, 2020, PULMONARY HYPERTENSI
  • [8] Comorbidities in Gaucher disease
    Berrah, Abdelkrim
    Hakem, Djennette
    [J]. MOLECULAR GENETICS AND METABOLISM, 2018, 123 (02) : S24 - S24
  • [9] Hepatopulmonary syndrome: A complication of type 1 Gaucher disease
    Bouguila, J.
    Rouatbi, H.
    Tej, A.
    Chabchoub, I.
    Trimech, B.
    El Ajmi, S.
    Essoussi, A. S.
    Boughammoura, L.
    [J]. REVUE DE PNEUMOLOGIE CLINIQUE, 2012, 68 (01) : 58 - 62
  • [10] CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: Clinical, histopathologic, and biochemical findings
    Burrow, Thomas A.
    Sun, Ying
    Prada, Carlos E.
    Bailey, Laurie
    Zhang, Wujuan
    Brewer, Amanda
    Wu, Steve W.
    Setchell, Kenneth D. R.
    Witte, David
    Cohen, Mitchell B.
    Grabowski, Gregory A.
    [J]. MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) : 233 - 241